Pharmaceutical - Markets & Marketing, Teva Pharmaceutical Industries


Popular Filters

Alexza’s partner Teva launches antipsychotic Adasuve in USA

Alexza’s partner Teva launches antipsychotic Adasuve in USA


US drug developer Alexza Pharmaceuticals says that its marketing partner, Israel-based generic drugs…

AdasuveAlexza PharmaceuticalMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical IndustriesUSA

Teva receives subpoenas over Copaxone and Azilect marketing

Teva receives subpoenas over Copaxone and Azilect marketing


The US Department of Justice is investigating Israel drugmaker Teva Pharmaceutical Industries’ marketing…

AzilectCopaxoneLegalMarkets & MarketingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Prostate cancer market to almost double to $8 billion by 2019, says GBI


The prostate cancer treatment market is forecast to increase from $4.1 billion in 2012 to $8 billion…

Active BiotechAstellas PharmaJohnson & JohnsonMarkets & MarketingOncoGenexOncologyPharmaceuticalTeva Pharmaceutical IndustriesXofigoXtandiZytiga

MS therapeutics market led by Copaxone


The multiple sclerosis (MS) therapeutics market has been forecast to increase at a compound annual growth…

CopaxoneMarkets & MarketingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Surge in drug approvals, R&D productivity and investor confidence to drive Pharma expansion through 2018, says Evaluate


According to the newly-released World Preview 2013 report from market intelligence firm Evaluate, the…

AbbVieBiotechnologyGilead SciencesGlobalHumiraMarkets & MarketingNovartisPfizerPharmaceuticalRegulationResearchsofosbuvirTeva Pharmaceutical Industries

Teva pays $40 million upfront to market Alexza's Adasuve in USA


The US subsidiary of Israeli generics giant Teva Pharmaceuticals Industries (NYSE: TEVA) has entered…

AdasuveAlexza PharmaceuticalLicensingMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical Industries

US FDA approves Lupin's generic version of Teva's Seasonique and Taro's Topicort


Indian drugmaker Lupin (BSE: 500257) saw its shares gain 2.3% to 659.65 rupees by close of trading on…

DayseeDermatologicalsGenericsLupinMarkets & MarketingNorth AmericaPharmaceuticalRegulationReproductiveSeasoniqueTaro PharmaceuticalsTeva Pharmaceutical IndustriesTopicort

Johnson & Johnson close to settling over Risperdal marketing; SEC probes Teva


US health care giant Johnson & Johnson (NYSE: JNJ) has reached "an agreement in principle'' with the…

FinancialGenericsInvegaJanssenJohnson & JohnsonLegalMarkets & MarketingNatrecorNorth AmericaPharmaceuticalRisperdalTeva Pharmaceutical Industries

Patient share of Teva/Lundbeck's Azilect for Parkinson's continues to grow


Through examination of US patient-level claims data, that patient share of Azilect (rasagiline) - from…

AzilectLundbeckMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical Industries

EU Commission focus now on Servier and others re-perindopril antitrust issues


The European Commission has informed French independent pharmaceutical company Servier and several of…

Cardio-vascularEuropeGenericsLegalMarkets & MarketingMylan LaboratoriesPatentsperindoprilPharmaceuticalServierTeva Pharmaceutical Industries

Novartis and Teva announce expansion plans in Russia


Swiss drug major Novartis (NOVN: VX) has signed an agreement with RT-Biotechprom, one of Russia's largest…

EuropeFinancialGenericsMarkets & MarketingNovartisPharmaceuticalRT-BiotechpromTeva Pharmaceutical Industries

FDA delays once-a-day Prezista approval; finds counterfeit of Teva's Adderall


US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Therapeutics division has received a complete…

AdderallAnti-viralsGenericsJanssenJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPrezistaRegulationTeva Pharmaceutical Industries

Opportunities for Pharma in narcolepsy


The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing…

BioprojectCephalonGenericsMarkets & MarketingNeurologicalNuvigilPharmaceuticalProvigilResearchTeva Pharmaceutical IndustriesUCBXyrem

Watson and Ranbaxy kick off genericization of Lipitor, launching their approved copies in USA


US generic drug major Watson Pharmaceuticals (NYSE: WPI) was the first to confirm yesterday that it has…

atorvastatinCardio-vascularGenericsLipitorMarkets & MarketingNorth AmericaPfizerPharmaceuticalRanbaxy LaboratoriesTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Recent Gilenya growth appears to be coming from initial trial among late adopters not expanded use among existing prescribers


After one year on the market, share of Swiss drug major Novartis’ (NOVN: VX) Gilenya (fingolimod),…

AvonexBiogen IdecCopaxoneGilenyaMarkets & MarketingNeurologicalNovartisPharmaceuticalTeva Pharmaceutical IndustriesTysabri

Back to top